Development of a human pancreatic islet-transplant program through a collaborative relationship with a remote islet-isolation center

John A. Goss, Sarah E. Goodpastor, F. Charles Brunicardi, Merle H. Barth, George D. Soltes, Alan J. Garber, Dale J. Hamilton, Rodolfo Alejandro, Camillo Ricordi

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Background. With the development of the Edmonton Protocol, pancreatic islet transplantation (PIT) now offers insulin-dependent diabetic patients metabolic stability. The PIT Food and Drug Administration (FDA) regulations, pancreatic islet isolation (PII) techniques, and clinical PIT protocols are challenging and make PIT program development daunting. Purpose. Review of the establishment of a PIT program through a collaborative relationship with a remote PIT/PII center. Methods. Four key elements are required: (1) development of a collaborative relationship with an established PIT/PII center, (2) achievement of institutional review board and FDA approval at both centers, (3) generation of standard operating procedures, and (4) development of a multidisciplinary PIT team. Results. Securing a collaborative relationship with an experienced PIT/PII center permitted our program to develop in less than 18 months. Twenty-two PITs were completed in the first clinical year. Conclusions. Collaboration with an experienced PIT/PII center allows developing programs to focus on patient safety and care, prudent use of pancreata, and consolidates PII expertise and experience.

Original languageEnglish
Pages (from-to)462-466
Number of pages5
JournalTransplantation
Volume77
Issue number3
DOIs
StatePublished - Feb 15 2004

Fingerprint

Islets of Langerhans Transplantation
Human Development
Islets of Langerhans
Transplants
United States Food and Drug Administration
Drug Approval
Program Development
Drug and Narcotic Control
Research Ethics Committees
Patient Safety
Pancreas
Patient Care
Insulin

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Development of a human pancreatic islet-transplant program through a collaborative relationship with a remote islet-isolation center. / Goss, John A.; Goodpastor, Sarah E.; Brunicardi, F. Charles; Barth, Merle H.; Soltes, George D.; Garber, Alan J.; Hamilton, Dale J.; Alejandro, Rodolfo; Ricordi, Camillo.

In: Transplantation, Vol. 77, No. 3, 15.02.2004, p. 462-466.

Research output: Contribution to journalArticle

Goss, John A. ; Goodpastor, Sarah E. ; Brunicardi, F. Charles ; Barth, Merle H. ; Soltes, George D. ; Garber, Alan J. ; Hamilton, Dale J. ; Alejandro, Rodolfo ; Ricordi, Camillo. / Development of a human pancreatic islet-transplant program through a collaborative relationship with a remote islet-isolation center. In: Transplantation. 2004 ; Vol. 77, No. 3. pp. 462-466.
@article{85dd9a4860c34569a7735de9d507292b,
title = "Development of a human pancreatic islet-transplant program through a collaborative relationship with a remote islet-isolation center",
abstract = "Background. With the development of the Edmonton Protocol, pancreatic islet transplantation (PIT) now offers insulin-dependent diabetic patients metabolic stability. The PIT Food and Drug Administration (FDA) regulations, pancreatic islet isolation (PII) techniques, and clinical PIT protocols are challenging and make PIT program development daunting. Purpose. Review of the establishment of a PIT program through a collaborative relationship with a remote PIT/PII center. Methods. Four key elements are required: (1) development of a collaborative relationship with an established PIT/PII center, (2) achievement of institutional review board and FDA approval at both centers, (3) generation of standard operating procedures, and (4) development of a multidisciplinary PIT team. Results. Securing a collaborative relationship with an experienced PIT/PII center permitted our program to develop in less than 18 months. Twenty-two PITs were completed in the first clinical year. Conclusions. Collaboration with an experienced PIT/PII center allows developing programs to focus on patient safety and care, prudent use of pancreata, and consolidates PII expertise and experience.",
author = "Goss, {John A.} and Goodpastor, {Sarah E.} and Brunicardi, {F. Charles} and Barth, {Merle H.} and Soltes, {George D.} and Garber, {Alan J.} and Hamilton, {Dale J.} and Rodolfo Alejandro and Camillo Ricordi",
year = "2004",
month = "2",
day = "15",
doi = "10.1097/01.TP.0000100397.86756.A3",
language = "English",
volume = "77",
pages = "462--466",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Development of a human pancreatic islet-transplant program through a collaborative relationship with a remote islet-isolation center

AU - Goss, John A.

AU - Goodpastor, Sarah E.

AU - Brunicardi, F. Charles

AU - Barth, Merle H.

AU - Soltes, George D.

AU - Garber, Alan J.

AU - Hamilton, Dale J.

AU - Alejandro, Rodolfo

AU - Ricordi, Camillo

PY - 2004/2/15

Y1 - 2004/2/15

N2 - Background. With the development of the Edmonton Protocol, pancreatic islet transplantation (PIT) now offers insulin-dependent diabetic patients metabolic stability. The PIT Food and Drug Administration (FDA) regulations, pancreatic islet isolation (PII) techniques, and clinical PIT protocols are challenging and make PIT program development daunting. Purpose. Review of the establishment of a PIT program through a collaborative relationship with a remote PIT/PII center. Methods. Four key elements are required: (1) development of a collaborative relationship with an established PIT/PII center, (2) achievement of institutional review board and FDA approval at both centers, (3) generation of standard operating procedures, and (4) development of a multidisciplinary PIT team. Results. Securing a collaborative relationship with an experienced PIT/PII center permitted our program to develop in less than 18 months. Twenty-two PITs were completed in the first clinical year. Conclusions. Collaboration with an experienced PIT/PII center allows developing programs to focus on patient safety and care, prudent use of pancreata, and consolidates PII expertise and experience.

AB - Background. With the development of the Edmonton Protocol, pancreatic islet transplantation (PIT) now offers insulin-dependent diabetic patients metabolic stability. The PIT Food and Drug Administration (FDA) regulations, pancreatic islet isolation (PII) techniques, and clinical PIT protocols are challenging and make PIT program development daunting. Purpose. Review of the establishment of a PIT program through a collaborative relationship with a remote PIT/PII center. Methods. Four key elements are required: (1) development of a collaborative relationship with an established PIT/PII center, (2) achievement of institutional review board and FDA approval at both centers, (3) generation of standard operating procedures, and (4) development of a multidisciplinary PIT team. Results. Securing a collaborative relationship with an experienced PIT/PII center permitted our program to develop in less than 18 months. Twenty-two PITs were completed in the first clinical year. Conclusions. Collaboration with an experienced PIT/PII center allows developing programs to focus on patient safety and care, prudent use of pancreata, and consolidates PII expertise and experience.

UR - http://www.scopus.com/inward/record.url?scp=1142286328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1142286328&partnerID=8YFLogxK

U2 - 10.1097/01.TP.0000100397.86756.A3

DO - 10.1097/01.TP.0000100397.86756.A3

M3 - Article

C2 - 14966428

AN - SCOPUS:1142286328

VL - 77

SP - 462

EP - 466

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 3

ER -